AB1257 EVALUATION OF ADHERENCE TO AND AGREEMENT WITH THE 2020 AMERICAN COLLEGE OF RHEUMATOLOGY GUIDELINE FOR THE MANAGEMENT OF GOUT BY US RHEUMATOLOGISTS

Background In 2020, the American College of Rheumatology (ACR) presented an updated gout treatment guideline. [1] Objectives this report, we evaluated US rheumatologists’ stated adherence to and agreement with 2020 ACR Guideline for Management Gout. Methods A 57-item questionnaire was administered rheumatologists, surveying their Stated scores were based on number recommendations reported be followed by rheumatologists in practice, whereas degree recommendations. Results All 201 approached completed questionnaire. Mean age participants 50 years, 54% had >15 years practice experience, ~70% private ( Table 1 ). overall score 11.5, a possible maximum 15, mean 7.7, 14. Rheumatologists less experience (≤8years; n=49) likely claim more individual than those (>8years; n=152) (mean score: 12.3 vs 11.3; p<0.05), who claimed see ≤75 patients 6 months (n=66) 12.1 11.2 have seen >75 (p<0.05). Approximately 78% follow guideline initiating urate lowering therapy (ULT) 89% prescribe allopurinol as first line ULT all patient types Figure Claimed dosing lower (43% 39%, febuxostat allopurinol, respectively). Approximately, 92% first-line flares from academic settings interleukin-1 inhibitor other settings. Conclusion The self-reported surveyed generally concordant However, there gaps knowledge among mainly concerning regimens. Reference [1]Fitzgerald JD, et al. Arthritis Care Res (Hoboken). 2020;72(6):744-760. 1. Demographics participating survey Characteristic Respondents (N=201) Age, (SD), 50.2 (10.9) Gender, male, n (% ) 135 (67.2) Practice setting, Academic medical center/academic-affiliated teaching hospital 47 (23.4) Community (non-teaching 14 (7.0) Private (solo/group 140 (69.7) Years ≤8 49 (24.4) 9–15 44 (21.9) 16–25 61 (30.4) ≥26 Patients per months, 1–75 66 (32.8) 76–150 79 (39.3) 151–225 25 (12.4) ≥226 31 (15.4) versus strong Gout *n=187; respondents did not administer concomitant anti-inflammatory prophylaxis asked about duration prophylaxis. †n=155; select oral colchicine or standard care flare management any prescribed dosage. state high use treatment. ‡ n=197; daily allopurinol. § n=81; febuxostat. ¶ Not tested agreement. ACTH, adrenocorticotropic hormone; CKD, chronic kidney disease; IL, interleukin; NPO, nothing mouth; NSAID, non-steroidal drug; SU, serum urate; ULT, urate-lowering therapy. Acknowledgements: NIL. Disclosure Interests Naomi Schlesinger Consultant of: Horizon Pharma, Novartis, JW LG chem, Sobi, ANI Protalix, Grant/research support from: Olatec, Michael Pillinger Therapeutics, Fortress Bioscience, Hikma Pharmaceuticals, Peter Lipsky Therapeutics.